About2019-05-21T14:13:44+00:00

ABOUT US

ABOUT US

Our Story

IVERIC bio is a gene therapy focused company developing innovative treatments for patients with orphan inherited retinal diseases with significant unmet medical needs. We have a diversified and scientifically compelling pipeline of product candidates.

At IVERIC bio we understand the critical importance of vision in the quality of life of patients.

Vision is our Mission

I-VER-IC: I (eye) – VER (veritas, truth) – IC (I see)

Leadership

An experienced team with a proven track record in clinical development and commercialization of novel therapies for retinal diseases.

Glenn P. Sblendorio
Glenn P. SblendorioChief Executive Officer and President
Kourous A. Rezaei, MD
Kourous A. Rezaei, MDChief Medical Officer
David F. Carroll
David F. CarrollChief Financial Officer
Keith Westby
Keith WestbyChief Operating Officer
Todd D.C. Anderman
Todd D.C. AndermanGeneral Counsel & Corporate Secretary
Evelyn Harrison
Evelyn HarrisonChief Clinical Operations Officer
Amy Sheehan
Amy SheehanChief Human Resources Officer

Board of Directors

Axel Bolte
Axel Bolte President and CEO, Inozyme Pharma, Inc.
Adrienne L. Graves
Adrienne L. GravesFormer Chief Executive Officer of Santen, Inc.
David R. Guyer, MD
David R. Guyer, MDExecutive Chairman of IVERIC bio's Board of Directors
Jane Pritchett Henderson
Jane Pritchett HendersonChief Financial Officer at Turnstone Biologics
David Redlick
David RedlickRetired Partner, WilmerHale and Retired Special Advisor, Leerink Partners
Calvin Roberts, MD
Calvin Roberts, MDChief Medical Officer, Eye Care at Bausch Health Companies
Glenn P. Sblendorio
Glenn P. SblendorioChief Executive Officer and President

Contact Us

For more information, contact us.

READ MORE

Glenn P. Sblendorio, M.B.A.

Chief Executive Officer and President

Glenn Sblendorio, M.B.A., is Chief Executive Officer and President of IVERIC bio. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the Board of Directors of IVERIC bio from 2013 to 2016 and rejoined the Board in May 2017. Prior to joining IVERIC bio, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.

Kourous A. Rezaei, M.D.

Senior Vice President and Chief Medical Officer

Dr. Rezaei serves as the Senior Vice President and Chief Medical Officer of IVERIC bio. He is a board certified ophthalmologist who specializes in the medical and surgical treatment of vitreoretinal diseases, and has been recognized with multiple awards in ophthalmology, including the Beem Fisher Award from the Chicago Ophthalmological Society and the American Academy of Ophthalmology Achievement Award. Dr. Rezaei had served on the Editorial Board of the journal of Investigative Ophthalmology & Visual Science (IOVS) and currently is a voting member on the Board of Directors of the American Society of Retina Specialists (ASRS). He has authored over 30 articles, five medical textbook chapters, and has presented over 80 abstracts in 26 countries. Dr. Rezaei is an Associate Professor of Ophthalmology and the Director of the Vitreoretinal Fellowship Program at Rush University Medical Center and is a senior partner at Illinois Retina Associates in Chicago. Previously, he was the Director of Vitreoretinal Service at the University of Chicago. Dr. Rezaei also founded “ChannelR”, a digital media education program for retina specialists.Dr. Rezaei received his medical degree from the University of Cologne in Germany. He served as chief resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.

David F. Carroll, M.B.A.

Chief Financial Officer

David Carroll, M.B.A, is the Chief Financial Officer of IVERIC bio. Mr. Carroll joined the Company in 2016 and has more than 25 years of experience in the life sciences industry. Prior to joining the Company, Mr. Carroll spent eight years at The Medicines Company in several senior financial leadership roles, including Vice President, Controller and most recently, Senior Vice President, Chief Accounting Officer. Earlier in his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Novartis, and Bristol-Myers Squibb.Mr. Carroll is a certified public accountant and received a BA from Ursinus College magna cum laude and an MBA from Rutgers University.

Keith Westby, M.B.A.

Senior Vice President and Chief Operating Officer

Keith Westby is Senior Vice President and Chief Operating Officer of IVERIC bio. Mr. Westby joined the Company in 2007 and has over 20 years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations. Prior to joining the Company, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen. Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a Bachelor of Science degree in Applied Physics from the State University of New York, College at Geneseo, a Master of Science degree in Engineering Management from Drexel University, and a Master of Business Administration degree from Columbia Business School.

Todd D.C. Anderman

Vice President, General Counsel & Corporate Secretary

Todd D.C. Anderman is Vice President, General Counsel & Corporate Secretary of IVERIC bio . Mr. Anderman joined the Company in 2015 after representing the company since 2012 while practicing corporate law at Wilmer Cutler Pickering Hale and Dorr LLP. While at WilmerHale, Mr. Anderman’s practice focused on representing life sciences and technology companies. Mr. Anderman began his career as a corporate attorney at Cravath, Swaine & Moore LLP. Mr. Anderman has extensive experience advising on merger, acquisition, divestiture, licensing and financing transactions. Mr. Anderman received his B.A. in Government and Philosophy from the College of Arts & Sciences at Cornell University and his J.D. from the University of Pennsylvania Law School.

Evelyn Harrison, M.B.A.

Chief Clinical Operations Officer

Evelyn Harrison, M.B.A., is the Chief Clinical Operations Officer of IVERIC bio. She brings more than 23 years of management and clinical research experience.Prior to joining IVERIC bio, Ms. Harrison was with Eyetech Pharmaceuticals, Inc., where she held the management positions of Vice President and Senior Vice President of Clinical Research and Development. While at Eyetech, Ms. Harrison, played a key role in the development and approval of Macugen® (pegaptanib sodium) for the treatment of wet age-related macular degeneration.

Ms. Harrison’s professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann-La Roche Inc., where she was Director of Clinical Operations, responsible for the development and implementation of strategic programs for Roche’s oncology franchise.

Ms. Harrison has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone marrow transplantation, organ transplantation, oncology and virology.

Ms. Harrison holds a B.A. degree in Biology from Hofstra University and a Master of Business Administration (M.B.A.) degree from Manhattan College.

Amy Sheehan

Senior Vice President and Chief Human Resources Officer

Amy Sheehan is the Senior Vice President & Chief Human Resources Officer at IVERIC bio. Ms. Sheehan joined the Company in 2014 and brings over 20 years of human resources experience in the biotechnology and manufacturing industries. Prior to joining IVERIC bio Ms. Sheehan led Human Resources for the Electronic Systems Division of Parker Hannifin, a publicly traded Fortune 250 global company. Earlier in Ms. Sheehan’s career she held leadership positions of increasing responsibility in human resources at OSI Pharmaceuticals, a publicly traded biotechnology company. Throughout Ms. Sheehan’s career she oversaw Human Resources teams and led successful HR strategies in talent acquisition, culture, total rewards, leadership development and training. She holds a Master’s degree in Human Resources Management and a Bachelor’s degree in psychology from Hofstra University.

Axel Bolte, MSc., M.B.A.

President and CEO, Inozyme Pharma, Inc. and Investment Advisor, HBM Healthcare Investments AG

Axel Bolte has served as a member of our board of directors since August 2007. Since March 2003, Mr. Bolte has served as investment advisor to HBM Partners AG, a provider of investment advisory services in the life sciences industry, also serving as a venture partner to HBM Partners AG beginning in February 2017. In February 2017, Mr. Bolte began serving as President and Chief Executive Officer of Inozyme Pharma Inc., a private biotechnology company. From March 2001 to February 2003, Mr. Bolte was an investment manager of NMT New Medical Technologies AG, a Swiss venture capital company focused on life sciences. Prior to joining NMT New Medical Technologies AG, Mr. Bolte served as a scientist at Serono SA, a biotechnology company. Mr. Bolte currently serves on the board of directors of Nabriva Therapeutics AG and previously served on the board of directors of PTC Therapeutics, Inc., both of which are publicly traded biotechnology companies. Mr. Bolte received a degree in Biochemistry from the Swiss Federal Institute of Technology, Zurich, Switzerland and an M.B.A. from the University of St. Gallen, Switzerland.

Adrienne L. Graves, Ph.D.

Former Chief Executive Officer of Santen, Inc.

Adrienne L. Graves, Ph.D., is a visual scientist by training and a global industry leader in ophthalmology.As the former Chief Executive Officer of Santen Inc., the US subsidiary of the 130-year-old Japanese pharmaceutical company, she successfully established a strong global presence, brought multiple ophthalmic products through development to approval and commercialization and led global teams through successful acquisitions and partnerships. At Santen, Dr. Graves served as Senior Vice President of Worldwide Clinical Development (US, Europe and Japan) for seven years and Chief Executive Officer for eight years. Prior to Santen, she spent nine years at Alcon, joining as Senior Scientist to establish Alcon’s first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in R&D, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology.

Dr. Graves currently serves as an Independent Director on multiple corporate boards including: Akorn, Inc., Greenbrook TMS, Nicox S.A., Oxurion NV, and Surface Pharmaceuticals. She is also a Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, Foundation Fighting Blindness Retinal Degeneration Fund, Retinal Global and KeepYourSight Foundation.

Dr. Graves cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic World Leaders (OWL). She received her A.B. in Psychology from Brown University, her Ph.D. in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

David R. Guyer, M.D.

Executive Chairman of IVERIC bio's Board of Directors

David Guyer, M.D. is a co-founder and Executive Chairman of our company. Dr. Guyer served as Chairman of our board of directors since our inception in January 2007 to January 2017 and as our Chief Executive Officer from April 2013 to January 2017. Prior to serving as our Chief Executive Officer, Dr. Guyer, served as a Partner at SV Life Sciences Advisers, LLC, a venture capital firm, from 2009 to 2013, and as a Venture Partner at SV Life Sciences from 2006 to 2009. In April 2013, Dr. Guyer resumed his role as Venture Partner at SV Life Sciences. He currently serves on the board of directors of Thrombogenics NV, which is a publicly traded biotechnology company. Dr. Guyer co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer and as a member of its board of directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a Professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Jane Pritchett Henderson

Chief Financial Officer at Turnstone Biologics

Jane Pritchett Henderson has more than 29 years of experience in the life sciences industry and health care investment banking. She currently serves as Chief Financial Officer at Turnstone Biologics, a clinical-stage immuno-oncology company. Prior to Turnstone, Ms. Henderson served as Senior Vice President of Corporate Development at Voyager Therapeutics, a publicly-traded, clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc. in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., until ISTA Pharmaceuticals was acquired by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson served as Chief Financial Officer and Head of Business Development at Axerion Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University and currently serves on the board of directors of Sesen Bio Inc., a publicly-traded biologics oncology company.

David Redlick

Retired Partner, WilmerHale and Retired Special Advisor, Leerink Partners

David Redlick has served as a member of our board of directors since January 2016 and was named our Lead Independent Director in February 2017. Mr. Redlick has served as a special advisor at Leerink Partners LLC, an investment bank focused on the healthcare industry, since January 2015. Previously, Mr. Redlick worked at Wilmer Cutler Pickering Hale and Dorr LLP, an international law firm, for over 40 years, serving as a Partner in the Corporate Practice Group until December 2014 and as Senior Counsel from January 2015 to December 2015. During his career at WilmerHale, Mr. Redlick also served as the co-chair of the Life Sciences Group, the co-chair of the Corporate Department and a member of the firm’s Executive Committee. Mr. Redlick received a B.A. from the University of Wisconsin and a J.D. from Harvard Law School.

Calvin Roberts, M.D.

Senior Vice President, Chief Medical Officer, Eye Care at Bausch Health Companies

 

Calvin W. Roberts, M.D. is a renowned specialist in cataract and refractive surgery. Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens.Dr. Roberts is a Senior Vice President and the Chief Medical Officer, Eye Care at Bausch Health Companies. Since 1982, Dr. Roberts is a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University, and a founding member of the board of directors of Alimera Sciences. Dr. Roberts previously served as a consultant to Allergan, Inc., Johnson & Johnson and Novartis. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and was a pioneer in the use of ophthalmic non-steroidals.

Dr. Roberts received an A.B. from Princeton University and his M.D. from the College of Physicians and Surgeons of Columbia University. Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston. Dr. Roberts currently serves as an Independent Director on multiple corporate boards.

Glenn P. Sblendorio, M.B.A.

Chief Executive Officer and President of IVERIC bio

Glenn Sblendorio, M.B.A., is Chief Executive Officer and President of IVERIC bio Corporation. He joined the Company in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the Board of Directors of IVERIC bio from 2013 to 2016 and rejoined the Board in May 2017. Prior to joining IVERIC bio, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.